Breakthrough in Vaccine 2020 Conference Event Name: 3rd International Conference Vaccines & Vaccination (Vaccine 2020)| May 20-21, 2020 Theme: Advances in Immunology & Vaccine Technology and Their Impact Aim and Scope: Vaccine is a biological preparation that provides active acquired immunity to a particular disease. Immunization currently prevents an estimated 2 to 3 million deaths [….]
IMMUNOTHERAPY Clinical Production of Car-T Autoglous Products at Frederick National LaboratoryRecent advancements in cancer immunotherapies and recent clinical trials with emerging cellular therapeutics such as tumor infiltrating lymphocytes (TILs), engineered T-cell receptors (TCRs), and Chimeric Antigen Receptors (CAR) T-cell therapies are generating huge interest and activity both academically and industrially. The treatment of cancer patients [….]
Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies Leidos’s ExGloH Leverages Entrepreneurial Science and Industry-Leading Support Infrastructure to Improve Global Health June 4, 2019 The seed for Leidos’s newest division—and virtual startup biotech—Explorations in Global Health (ExGloH) was planted nearly 20 years ago. In 2000, Leidos secured [….]
NextCure files for $92M IPO to advance Cancer Immunotherapy Pipeline April 29, 2019 NextCure, a clinical-stage biotech in Beltsville, MD developing cancer immunotherapies, announced the terms for its IPO that could raise up to $92M by offering 5M common shares at $14 – $16. The company has applied to trade on NASDAQ under the symbol, [….]
4 Vaccine and Immunotherapy Companies in Maryland That Are Redefining the Capabilities of Modern Medicine Maryland’s World Leading Vaccine Hub Showcased at Fourth Annual MTC Life Science Breakfast January 22, 2019 It might be cold and snowy across the DMV, but one thing is for sure—vaccine and immunotherapy companies are hot in the BioHealth Capital [….]
Immune-Oncology Symposium
Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018 Teri Heiland, Ph.D. is the Senior Vice President of Research and Development, and Co-founder, at Immunomic Therapeutics, Inc., a clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. [….]
